Reprogramming the course of cancer and diabetes


Our technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.


We are developing gene therapies for patients with cancer and diabetes to bring new therapies to large patient populations. Our lead product candidate, REQORSA™ immunogene therapy, is designed to be administered in combination with other therapies, including targeted therapies and immunotherapies, for non-small cell lung cancer.

Management Team

We have assembled a multidisciplinary team of executives and advisors with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.

Learn More

About Us

At Genprex, we are committed to developing life-changing gene therapies for patients with cancer and diabetes through unique, innovative science. We are dedicated in our efforts to helping patients with limited or no treatment options to have access to new and advanced therapies to more effectively treat their disease. 

What they’re saying

In the Media

Catch up with our

Latest News

Genprex’s REQORSA™ Immunogene Therapy: The First Systemic Gene Therapy Used for Cancer

Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is a leader in gene therapy with a systemic gene therapy in development for non-small cell lung cancer (NSCLC).

Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer

Multiple clinical trial sites to be opened under oncology research network collaboration

Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes

HC Wainwright BIOCONNECT 2022 Virtual Conference – January 10-13

Biotech Showcase 2022 – January 10-13

Precision: Lung Cancer World R&D Virtual Summit – January 25-26

CEO Roadshow – January 26

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Pipeline Expansion Enables Company to Target Entire Lung Cancer Market with REQORSA™